Table 1.
Baseline characteristics of enrolled patients
| Variables | No. of patients (N=89) | % |
|---|---|---|
| Age (years-old) | 61.3 (IQR 56.4-67.8) | 100 |
| Male gender | 75 | 84.3 |
| BW (kg) | 66.3 (IQR 57.0-74.9) | 100 |
| Etiology | ||
| HBV/HCV/NBNC | 69/10/10 | 77.6/11.2/11.2 |
| ECOG PS 0/1/2 | 35/49/5 | 39.3/55.1/5.6 |
| Child-Pugh A/B | 76/13 | 85.4/14.6 |
| ALBI grade I/II/III* | 34/50/1 | 40.0/58.8/1.2 |
| Portal vein thrombosis | 45 | 50.6 |
| Vp3/4 | 26/16 | 57.8/35.6 |
| Esophageal varices | 22 | 24.7 |
| Extra-hepatic metastasis | 35 | 39.3 |
| AFP (ng/ml) | 354 (IQR 18-3596) | 100 |
| ≥400 | 43 | 48.3 |
| BCLC stage B/C | 23/66 | 25.8/74.2 |
| Tumor size, maximum (cm) | 8.0 (IQR 4.3-11.0) | 100 |
| Beyond up-to-seven | 76 | 85.4 |
| Lines of systemic therapy | ||
| 1/≥2 | 49/40 | 55.1/44.9 |
| Prior resection history | 12 | 13.5 |
| Prior locoregional therapy | 54 | 60.7 |
| TACE/RFA/HAIC/RT | 48/18/4/11 | 88.9/33.3/7.4/20.4 |
| Previous TKI therapy | 33 | 37.1 |
| Sorafenib/Regorafenib/Lenvatinib/cabozantinib | 19/7/14/1 | 57.6/21.2/42.4/3.0 |
| Observation period (months) | 7.2 (IQR 4.0-11.0) | 100 |
| Treatment cycles | 4 (IQR 3-6) | 100 |
| Mortality | 29 | 32.6 |
Abbreviations: AFP, Alpha-fetoprotein; ALBI, Albumin-bilirubin index; BCLC, Barcelona Clinic Liver Cancer; BW, Body weight; ECOG, Eastern Cooperative Oncology Group; HAIC, Hepatic artery chemotherapy infusion; HBV, Hepatitis B virus; HCV, hepatitis C virus; NBNC, Non-hepatitis B and C virus; RFA, Radiofrequency ablation; RT, Radiotherapy; TACE, Transarterial chemoembolization; TKI, Tyrosine kinase inhibitor.
*
missing data.